Against the looming backdrop of patent expirations and the
need to minimise expenses the Pharma industry continues to
look towards the Asia Pacific region to outsource its’
R&D activities. As the pace of change continues to
gain momentum at an unprecedented rate it is not only the
bigger players such as China and India that are benefiting
but other countries such as Singapore, Malaysia, Taiwan
and South Korea have sought to create an infrastructure
that will support this trend through academic innovation
and government investment.
This has created a scenario where the Asia Pacific region
is becoming an increasingly attractive proposition for
fully outsourced drug discovery programmes from lead
identification through lead optimisation and beyond. This
trend has been further enhanced by a significant increase
in experts with the necessary technical expertise who had
previously worked in the West now returning to Asia to
assume leadership roles whilst still maintaining their
contacts at a global level.
Building on the success of last years APRADOC the 2nd
congress will drill down even deeper into the current
challenges facing pharma companies who are already
outsourcing their R&D activities to the Asia Pacific
regions or looking to do so in the near future. As well as
looking at the current ‘state of play’ the 2 day
conference programme will also take hard look at the
future and the impact this movement will have on the
pharmaceutical as a whole.
Some of the topics under review during keynote
presentations and interactive panel discussions will
include –
Potential partnering opportunities with
companies and research centres in the development of
drug candidates
Current ongoing government initiatives in
countries such as Singapore, South Korea, Malaysia and
China
Growth trends in the global pharmaceutical
market. How Asia is becoming increasingly important
Opportunities for the treatment of localised
diseases
The changing face of R&D in Asia Pacific –
meeting localised healthcare needs instead of those of
the West
Does Intellectual Property Protection (IPP)
still pose an obstacle too outsourced clinical
activity
Re - examining the role of Asia as an
outsourcing destination for clinical trials. How real
are the potential cost savings?
The increasing role of regional CROs in the
drug discovery process
What steps are Asian countries taking to
streamline regulatory procedures
Managing IT and data management outsourcing to
increase return on investment
2011
Sponsors
Copyright: Global Engage Ltd.
Registered in England. No: 6950636
